STYLE SHEET
GLOBAL CSS
COLORS
ANIMATIONS
MEDIA QUERY
SPACING SYSTEM

Why only for healthcare professionals?

The content on these information pages is directed solely at you if you are a doctor, nurse, or pharmacist, as it concerns treatment with prescription medicines.

Please confirm that you are a healthcare professional (healthcare assistant, nurse, doctor, psychologist, or other licensed healthcare professional).

Back to main page

Confirm and continue

Press release
February 5, 2026

Yazen presents new data on digital obesity care at NOM 2026

Yazen presents an oral scientific abstract at the Nordic Obesity Meeting (NOM26), highlighting high-volume patient–caregiver interactions in a fully digital obesity care model.

Yazen Health Presents New Real-World data on Digital Obesity Care at the 3rd Nordic Obesity Meeting 2026 (NOM26)

Today, at the Nordic Obesity Meeting (NOM26) in Stockholm, Yazen presented new scientific insights into patient engagement and continuity of care within a fully digital obesity treatment model. Over two days in Stockholm, Nordic Obesity Meeting brings together more than 200 participants on site, alongside a digital audience on about 100 participants, representing leading obesity expertise from all over the world.

On the first day of the meeting, Yazen presented an oral scientific abstract entitled “High-Volume Patient–Caregiver Interactions in a Fully Digital Obesity Care Model” as part of the official scientific programme. The presentation was given by MD and researcher Felix Wittström.

The abstract is based on longitudinal real-world data from Yazen’s digital care platform and describes the scale and frequency of interactions between approximately 50,000 patients and a multidisciplinary care team, including physicians, dietitians, physiotherapists, health coaches and psychologists, when needed. Across three full years (156 weeks), 7.7 million messages were exchanged between patients and their caregivers, and 2.3 million weight entries were logged. The results highlight how a fully digital care model, with a high level of patient–caregiver interaction, enables continuous patient engagement and sustained self-monitoring over time.

Felix Wittström, MD and researcher, Yazen Health

These findings illustrate the level of interaction and ongoing support that becomes possible when obesity care is delivered through a fully digital model, said Felix Wittström, presenter of the abstract. Such continuous access may be particularly important for supporting long-term treatment adherence in obesity care.

Key insights presented:

  • High volumes of patient–caregiver communication, enabled by continuous digital access
  • Sustained patient engagement, including frequent self-monitoring of weight within the digital platform
  • High treatment retention in the digital obesity care model, compared with what has been reported in other care settings, which may support long-term obesity treatment outcomes

Yazen’s participation at the Nordic Obesity Meeting 2026 reflects the company’s continued commitment to generating and sharing real-world evidence that informs the development of patient-centred, long-term obesity care.

Read the abstract in full here


For more information:
Fredrik Pallin, Head of PR Yazen
fredrik.pallin@yazen.com
+46 708 114 115

About Yazen Health
Founded by health care professionals in Sweden in 2021, Yazen is pioneering a revolutionary approach to obesity treatment through digital healthcare. Combining groundbreaking GLP-1 and GLP-1/GIP weight loss medications with comprehensive lifestyle guidance, Yazen offers a holistic, data-driven solution.

With over 20,000 active users who have collectively lost 200+ tons, Yazen stands out in treating the global obesity epidemic. Its innovative model provides personalised obesity programmes through an advanced yet user-friendly app, enhancing access to specialist care including doctors, coaches, dietitians, psychologists and physiotherapists.

More news

Yazen Highly Commended in the HTN Now 2025/26 Awards

Yazen’s work powering digital patient transformation for sustainable weight care is recognised by the HTN Now 2025/26 Awards in the category of Digital Patient Transformation.

Weight Loss Drugs Linked to Long-Term Alcohol Reduction

Weight management patients show lasting alcohol reduction with health benefits extending beyond temporary Dry January abstinence, new research reveals.

GLP-1 Weight Loss Drugs: How to Spot Unsafe Sellers

Discover why weight loss medications must come from registered clinicians. Learn to identify illegitimate sellers and protect yourself from dangerous counterfeit GLP-1 treatments in the UK.